Korean Air Says Turbulence is Knocking Instant Noodles Off Menu

FILE - Passengers approach a Korean Air counter at Gimpo airport in Seoul, South Korea, Oct. 25, 2012. (AP Photo/Lee Jin-man, File)
FILE - Passengers approach a Korean Air counter at Gimpo airport in Seoul, South Korea, Oct. 25, 2012. (AP Photo/Lee Jin-man, File)
TT

Korean Air Says Turbulence is Knocking Instant Noodles Off Menu

FILE - Passengers approach a Korean Air counter at Gimpo airport in Seoul, South Korea, Oct. 25, 2012. (AP Photo/Lee Jin-man, File)
FILE - Passengers approach a Korean Air counter at Gimpo airport in Seoul, South Korea, Oct. 25, 2012. (AP Photo/Lee Jin-man, File)

Turbulence is knocking a beloved instant-noodle offering off Korean Air's economy menu, The Associated Press reported.
Cups of Shin Ramyun instant noodles, a favorite among Korean Air travelers over the years, will no longer be available for economy-class passengers starting Aug. 15, a spokesperson for the Seoul-based airline said.
“This decision is part of proactive safety measures in response to increased turbulence, aimed at preventing burn accidents,” Korean Air said.
The instant noodles are currently part of Korean Air's in-flight snack service, which is a self-serve bar beyond meals available for economy passengers on long-haul trips. In this week's announcement, the carrier added that it had “renewed” economy's snack options to instead include offerings like sandwiches, corn dogs and hot pockets.
But business- and first-class passengers will still get their noodles. Korean Air told the BBC that the noodles are brought individually to business- and first-class travelers, reducing spill risks.
Concern about the dangers of serving hot food and liquids on airplanes isn't new. Over the years, several carriers have faced lawsuits from customers who say they suffered serious burns after having hot coffee, for example, spilled on them during a flight. And, while legal precedent may vary around the world, the European Union’s highest court ruled in 2019 that an airline can be held liable if a passenger is injured in this way, even if turbulence or other flight-related factors didn’t cause the spill.
But turbulence, of course, still adds to risk. Flying through unstable air can make balancing something like soup or a hot beverage in-flight all the more precarious.
Numerous turbulence-related injuries have been reported over the years, but most incidents are minor — and airlines have made steady improvements in reducing accident rates. Those include suspending cabin service when needed or taking extra caution when distributing certain refreshments.
Still, rough air might be getting harder and harder to avoid. Some meteorologists and aviation analysts note reports of turbulence encounters are on the rise, pointing to the potential impacts climate change may have on flying conditions.



Weight Loss Drug Cut Heart Failure Risk by 38% in Trial

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
TT

Weight Loss Drug Cut Heart Failure Risk by 38% in Trial

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights

Trial results show Eli Lilly's weight loss drug Zepbound reduces the risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure, the company said on Thursday as it continues to build a case for the medication's wider health benefits.

The drug, also known as tirzepatide, reduced the risk of a composite of heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death by 38% compared to a placebo, according to Reuters.

The trial enrolled 731 patients across 10 countries who have heart failure with preserved ejection fraction and obesity.

The condition "accounts for nearly half of all heart failure cases, and in the US almost 60% of those impacted also live with obesity," Jeff Emmick, Lilly senior vice president, product development, said in a statement.

Lilly said the study also showed the drug significantly improved heart failure symptoms and physical limitations.

Heart failure is a condition in which the heart is unable to pump enough blood to meet the body's needs. It is associated with a high burden of symptoms and physical limitations affecting daily life, including fatigue, shortness of breath, reduced ability to exercise and swelling of extremities.

Trial patients on tirzepatide were given weekly injections of the highest dose they could tolerate, up to 15 milligrams, and were followed for a median of two years.

The drug led to 15.7% weight loss in the combined population of people with and without type 2 diabetes, compared with 2.2% for the placebo, Lilly said. For the non-diabetes patients, weight loss was 13.9%.

Zepbound, also sold under the brand name Mounjaro for type 2 diabetes, is part of a top-selling class of drugs designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow digestion and decrease appetite.

Lilly said the most common side effects for trial patients on tirzepatide were diarrhea, nausea, constipation and vomiting.

The company said it plans to submit the heart failure results to the US Food and Drug Administration and other regulatory agencies starting later this year. The findings will also be presented at an upcoming medical meeting and submitted to a peer-reviewed journal.

Novo Nordisk has reported data showing its GLP-1 weight loss drug Wegovy reduces heart failure symptoms.